home / stock / mbrx / mbrx articles
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street ...
Moleculin Biotech Inc (NASDAQ: MBRX) provided a preliminary update on recent clinical activity from annamycin lead development programs. ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data PR Newswire Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1 st and 2 nd line AML subjects (N=13) ...
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 PR Newswire Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the ...
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin PR Newswire – Company appoints internationally renowned clinician, Martin S. Tallman , MD as inaugural clinician member HOUSTON , May 1, 2024 /PRNewswire/ --...